Herald of the Bauman Moscow State Technical University, Series Natural Sciences. Vol. 107. 2023. P.. 110-125
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers. © The Author(s) 2023.
Authors
Akhuba L. , Tigai Z. , Shek D.
Journal
Publisher
OAE Publishing Inc.
Issue number
2
Language
English
Pages
327-331
State
Published
Link
Volume
6
Year
2023
Organizations
- 1 School of Health Sciences, Western Sydney University, Sydney, 2145, NSW, Australia
- 2 Accreditation Centre, RUDN University, Moscow, 117198, Russian Federation
- 3 Blacktown Clinical School, Western Sydney University, Sydney, 2145, NSW, Australia
- 4 Blacktown Mt Druitt Hospital, Sydney, 2145, NSW, Australia
- 5 Westmead Institute for Medical Research, Sydney, 2145, NSW, Australia
Keywords
immune-checkpoint inhibitors; microenvironment; Pancreatic cancer; tumor resistance
Share
Other records
Андрология и генитальная хирургия. Vol. 24. 2023. P.. 31-40